Creative Touch Permanent Makeup and Aesthetics

Filaggrin is the multifunctional scaffolding protein essential for both the structural integrity and the biochemical environment of the epidermis. Synthesised as profilaggrin in the stratum granulosum, it coordinates the compaction of keratin filaments to create the dense architecture of the corneocyte. Its subsequent degradation into Natural Moisturizing Factors (NMF) and acidic metabolites (urocanic acid and PCA) is the primary driver of surface hydration and the maintenance of the acid mantle. In clinical practice, filaggrin status is a proxy for barrier resilience; its suppression by Type 2 inflammatory cytokines creates a foundational deficit in hydration and pH that topical moisturisers cannot bypass.

Filaggrin is a structural protein that performs two distinct and equally important functions in the stratum corneum: it physically aggregates keratin filaments to create the flattened, dense architecture of a mature corneocyte, and it subsequently degrades into the hygroscopic compounds that form natural moisturising factor (NMF), the primary source of intracellular water retention in the outer barrier. Both functions are disrupted in filaggrin deficiency (whether from genetic mutation or inflammatory suppression) making it one of the most clinically consequential single proteins in skin barrier biology. When filaggrin is inadequate, the barrier loses both its structural organisation and its internal hydration capacity simultaneously.

From Profilaggrin to Natural Moisturising Factor

Filaggrin begins as profilaggrin, a large precursor protein stored in the keratohyalin granules of the stratum granulosum. As keratinocytes complete their terminal differentiation into corneocytes, profilaggrin is cleaved into individual filaggrin monomers. These monomers bind and compact the keratin filament network, physically collapsing the cell into the characteristic flat disc shape of a corneocyte. This compaction step is what creates the protein-dense, structurally rigid bricks of the stratum corneum. ^[1]

In the outer stratum corneum, the story does not end there. Filaggrin undergoes progressive proteolytic degradation through the action of caspase-14, calpain-1, and bleomycin hydrolase, releasing its constituent amino acids and their metabolic derivatives. The products (collectively called NMF) include pyrrolidone carboxylic acid (PCA, derived from glutamine), trans-urocanic acid (UCA, derived from histidine), free amino acids including histidine, serine, and glycine, and other hygroscopic compounds. NMF components are intensely water-attracting, maintaining corneocyte hydration against the osmotic gradient that would otherwise drive water out of the cell. Both PCA and UCA contribute to stratum corneum acidification through their organic acid character – together, filaggrin-derived breakdown products account for two of the four mechanisms that maintain the acid mantle’s pH 4.5–5.5 range, alongside free fatty acid generation and lactic acid from eccrine sweat. Filaggrin deficiency therefore simultaneously removes two of those four acidification sources, a detail with direct clinical consequences: FLG-deficient skin is disproportionately dependent on free fatty acids for acid mantle maintenance, and disproportionately vulnerable whenever a second acidification mechanism is disrupted. Filaggrin deficiency thus creates a concurrent NMF shortage, structural barrier defect, and two-pathway acid mantle impairment from the absence of one protein. ^{[12] [4]}

The Dual-Life of Filaggrin

Two Routes to Filaggrin Deficiency

Genetic deficiency arises from loss-of-function mutations in the FLG gene. The most common variants in European populations are R501X and 2282del4. FLG null mutations are found in 15–40% of atopic dermatitis patients, and heterozygous FLG mutations are present in approximately 9% of the European general population. Critically, even heterozygous mutation carriers, who retain one functional copy, show measurably impaired barrier function compared with wild-type individuals – confirming that filaggrin abundance, not merely its presence, is dose-dependent for barrier integrity. ^[6]

Clinical Pearl FLG mutation carriers in hard water areas face a mechanistically specific compounded risk. A longitudinal study found a hazard ratio of 2.72 for atopic eczema in this group, with a statistically significant interaction term confirming the combined effect exceeds what either factor predicts independently. ^[8] The mechanism is precise: FLG mutations remove PCA and UCA as acidification sources (two of the four acid mantle pathways); hard water then depletes free fatty acids through calcium stearate formation (a third). For FLG mutation carriers washing in South Yorkshire water, three of the four acid mantle acidification mechanisms are simultaneously compromised with every wash – making this the highest-risk group for hard water-associated barrier dysfunction, and the group for whom syndet cleansers, chelating ingredients, and FFA-restoring interventions have the highest potential yield.

Acquired deficiency operates through cytokine suppression and is often overlooked in clinical discussions focused on genetics. IL-4 and IL-13, the type 2 inflammatory cytokines characteristically elevated in atopic dermatitis, directly suppress FLG gene expression in keratinocytes regardless of FLG genotype. Primary keratinocyte research has demonstrated that IL-4 and IL-13 exposure reduces filaggrin expression to approximately 25% of baseline (a 75% reduction) in cells with entirely normal FLG genes. The practical implication is significant: a client with wild-type FLG who develops active atopic inflammation can acquire a filaggrin deficiency comparable in severity to that of a heterozygous mutation carrier, and this deficiency is fully reversible if the inflammatory environment is resolved. The barrier damage from acquired filaggrin suppression is not a genetic inevitability; it is a downstream consequence of cytokine activity that responds to appropriate anti-inflammatory intervention. ^[7]

IL-4 and IL-13 also suppress loricrin and involucrin alongside filaggrin (two other epidermal differentiation complex proteins) meaning the acquired barrier defect from type 2 inflammation is broader than filaggrin alone. The filaggrin suppression is, however, the most directly measurable and clinically relevant component of this wider differentiation impairment. ^[3]

A third suppression route operates independently of the type 2 inflammatory pathway. Cortisol, when chronically elevated through psychological stress, suppresses filaggrin expression directly through glucocorticoid receptor signalling in keratinocytes – GR-null keratinocyte models show filaggrin mRNA reduced to approximately 22% of wild-type levels, and cortisol exposure in human keratinocytes directly decreases FLG mRNA in a GR-dependent manner. ^{[13] [10]} This means the barrier consequences of chronic stress are not limited to the HPA axis effects on cholesterol synthesis described in the Cortisol entity – they include direct impairment of filaggrin production and, through it, reduced NMF generation and further acid mantle acidification loss. The three acquisition routes (IL-4/IL-13 cytokine suppression, cortisol, and genetic baseline) are independent, which means they can compound simultaneously in the same client.

What Filaggrin Deficiency Does at Each Layer

Filaggrin deficiency does not create a single barrier failure. It initiates a cascade of structural and biochemical changes across the full depth of the stratum corneum, each feeding into the next. Understanding where in this sequence a client’s presentation sits helps identify which interventions are most relevant.

A note on the last two rows: the surface pH and microbiome consequences are not simply downstream of the structural failure – they actively perpetuate it. S. aureus proteases degrade tight junction proteins and directly suppress filaggrin expression, whilst the alkaline pH they favour further impairs ceramide processing. Resolving the microbial environment is therefore part of the same recovery cycle rather than a secondary concern. ^[12]

The Acid Mantle Connection and the Feedback Loop

Because UCA, the histidine-derived NMF component, is one of the primary contributors to stratum corneum acidification, filaggrin deficiency reduces the acid mantle pH independently of free fatty acid levels. Higher stratum corneum pH impairs the activity of acidic sphingomyelinase and beta-glucocerebrosidase (the enzymes that convert ceramide precursors to active barrier ceramides) creating a secondary ceramide production deficit downstream of the filaggrin problem. This is one of the mechanisms through which barrier damage from filaggrin deficiency cascades into ceramide depletion even when ceramide synthesis pathways are otherwise intact. ^[5]

The feedback loop is self-reinforcing: lower filaggrin → lower NMF and UCA → higher stratum corneum pH → impaired ceramide processing → ceramide shortfall → increased allergen penetration → more IL-4/IL-13 → further filaggrin suppression. Addressing any single step without addressing the others produces slower and less complete recovery than an approach that targets the inflammatory suppression and provides direct structural lipid support simultaneously.

The NMF & pH Cascade

Restoring Filaggrin Expression

For acquired filaggrin deficiency, the most direct restoration route is resolving the IL-4/IL-13 environment that is suppressing FLG gene expression. This is precisely the mechanism behind dupilumab’s effectiveness in atopic dermatitis: as a dual IL-4/IL-13 receptor antagonist, it demonstrably increases FLG expression in lesional skin as the cytokine suppression is lifted. Professional treatments that reduce type 2 inflammatory signalling – cold atmospheric plasma, polynucleotides – work on the same pathway at a topical level, restoring the conditions for normal filaggrin expression rather than supplying filaggrin directly. ^[6]

Niacinamide supports filaggrin expression through keratinocyte differentiation pathways, as part of its broader barrier lipid upregulation activity, making it a practical topical active that addresses filaggrin and ceramide synthesis within the same routine step. The L-histidine finding is worth noting with appropriate evidence framing: a pilot study and in vitro organotypic model demonstrated that oral L-histidine supplementation increased 37kDa filaggrin monomer formation concentration-dependently, with clinical improvements in atopic dermatitis comparable to a mid-potency topical corticosteroid in a small trial. This is preliminary evidence that deserves further investigation, not a clinical recommendation, but it establishes L-histidine as a nutritionally meaningful precursor to NMF production for clients with documented filaggrin pathway compromise. ^[14]

Clinical Presentation of Filaggrin Deficit